Functional deregulation of KIT: Link to mast cell proliferative diseases and other neoplasms

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 219-237

  Cruse, Glenn ^a   Metcalfe, Dean D ^a   Olivera, Ana ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

KIT inhibitors; KIT mutations; KIT signaling; KIT trafficking; Mastocytosis

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; DASATINIB; IMATINIB; IMMUNOGLOBULIN E; MIDOSTAURIN; NILOTINIB; STEM CELL FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; LIGAND BINDING; LYMPHOPROLIFERATIVE DISEASE; MAST CELL; MASTOCYTOSIS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; BONE MARROW; DRUG EFFECTS; EXON; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

BONE MARROW; CELL PROLIFERATION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; MAST CELLS; MASTOCYTOSIS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 84898818894     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.002     Document Type: Review

References (125)

1. Yarden Y., Kuang W.J., Yang-Feng T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987, 6:3341-3351.
2. Qiu F.H., Ray P., Brown K., et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988, 7:1003-1011.
3. Flanagan J.G., Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990, 63:185-194.
4. Broudy V.C. Stem cell factor and hematopoiesis. Blood 1997, 90:1345-1364.
5. Toksoz D., Zsebo K.M., Smith K.A., et al. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 1992, 89:7350-7354.
6. Reber L., Da Silva C.A., Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006, 533:327-340.
7. Miyazawa K., Williams D.A., Gotoh A., et al. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 1995, 85:641-649.
8. Ashman L.K. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999, 31:1037-1051.
9. Ogawa M., Matsuzaki Y., Nishikawa S., et al. Expression and function of c-kit in hemopoietic progenitor cells. JExp Med 1991, 174:63-71.
10. Bowie M.B., Kent D.G., Copley M.R., et al. Steel factor responsiveness regulates the high self-renewal phenotype of fetal hematopoietic stem cells. Blood 2007, 109:5043-5048.
11. Kitamura Y., Oboki K., Ito A. Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am 2006, 26:387-405.
12. Jensen B.M., Akin C., Gilfillan A.M. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 2008, 154:1572-1582.
13. Lennartsson J., Jelacic T., Linnekin D., et al. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005, 23:16-43.
14. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999, 31:1053-1074.
15. Galli S.J., Tsai M., Wershil B.K., et al. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol 1995, 107:51-53.
16. Oliveira S.H., Taub D.D., Nagel J., et al. Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis. Blood 2002, 100:4291-4297.
17. Krishnamoorthy N., Oriss T.B., Paglia M., et al. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 2008, 14:565-573.
18. Yuan Q., Austen K.F., Friend D.S., et al. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). JExp Med 1997, 186:313-323.
19. Heinemann A., Sturm G.J., Ofner M., et al. Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. JAllergy Clin Immunol 2005, 116:820-826.
20. Huizinga J.D., Thuneberg L., Kluppel M., et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373:347-349.
21. Al-Muhsen S.Z., Shablovsky G., Olivenstein R., et al. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 2004, 34:911-916.
22. Hollenbeck S.T., Sakakibara K., Faries P.L., et al. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. JSurg Res 2004, 120:288-294.
23. Hirata T., Kasugai T., Morii E., et al. Characterization of c-kit-positive neurons in the dorsal root ganglion of mouse. Brain Res Dev Brain Res 1995, 85:201-211.
24. Reber L.L., Marichal T., Galli S.J. New models for analyzing mast cell functions invivo. Trends Immunol 2012, 33:613-625.
25. Oiso N., Fukai K., Kawada A., et al. Piebaldism. JDermatol 2013, 40:330-335.
26. Sekido Y., Takahashi T., Ueda R., et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993, 53:1709-1714.
27. Sihto H., Sarlomo-Rikala M., Tynninen O., et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. JClin Oncol 2005, 23:49-57.
28. Lu H.Y., Zhang G., Cheng Q.Y., et al. Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol Lett 2012, 4:89-93.
29. Bachet J.B., Landi B., Laurent-Puig P., et al. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer 2013, 49:2531-2541.
30. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
31. Ashman L.K., Ferrao P., Cole S.R., et al. Effects of mutant c-Kit in early myeloid cells. Leuk Lymphoma 1999, 34:451-461.
32. Lennartsson J., Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012, 92:1619-1649.
33. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
34. Rammohan A., Sathyanesan J., Rajendran K., et al. Agist of gastrointestinal stromal tumors: a review. World J Gastrointest Oncol 2013, 5:102-112.
35. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564.
36. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
37. Brockow K., Metcalfe D.D. Mastocytosis. Chem Immunol Allergy 2010, 95:110-124.
38. Tran A., Tawbi H.A. Apotential role for nilotinib in KIT-mutated melanoma. Expert Opin Investig Drugs 2012, 21:861-869.
39. Alexeev V., Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. JInvest Dermatol 2006, 126:1102-1110.
40. Malaise M., Steinbach D., Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 2009, 4:77-82.
41. Ashman L.K., Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs 2013, 22:103-115.
42. Odenike O., Thirman M.J., Artz A.S., et al. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?. Semin Oncol 2011, 38:196-214.
43. Kirshenbaum A.S., Kessler S.W., Goff J.P., et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. JImmunol 1991, 146:1410-1415.
44. Gurish M.F., Austen K.F. Developmental origin and functional specialization of mast cell subsets. Immunity 2012, 37:25-33.
45. Rivera J., Gilfillan A.M. Molecular regulation of mast cell activation. JAllergy Clin Immunol 2006, 117:1214-1225. [quiz: 1226].
46. Gilfillan A.M., Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006, 6:218-230.
47. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 2013, 90:89-98.
48. Piao X., Bernstein A. Apoint mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996, 87:3117-3123.
49. Nagata H., Okada T., Worobec A.S., et al. c-kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997, 113:184-186.
50. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312-314.
51. Buttner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. JInvest Dermatol 1998, 111:1227-1231.
52. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. JInvest Dermatol 2010, 130:804-815.
53. Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
54. Molderings G.J., Kolck U.W., Scheurlen C., et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007, 42:1045-1053.
55. Chan E.C., Bai Y., Bandara G., et al. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. Exp Hematol 2013, 41:870-881.e2.
56. Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63:226-232.
57. Yuzawa S., Opatowsky Y., Zhang Z., et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007, 130:323-334.
58. Lemmon M.A., Pinchasi D., Zhou M., et al. Kit receptor dimerization is driven by bivalent binding of stem cell factor. JBiol Chem 1997, 272:6311-6317.
59. Mol C.D., Dougan D.R., Schneider T.R., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. JBiol Chem 2004, 279:31655-31663.
60. Mol C.D., Lim K.B., Sridhar V., et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. JBiol Chem 2003, 278:31461-31464.
61. Blume-Jensen P., Claesson-Welsh L., Siegbahn A., et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991, 10:4121-4128.
62. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004, 116:191-203.
63. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004, 61:2535-2548.
64. Linnekin D., DeBerry C.S., Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. JBiol Chem 1997, 272:27450-27455.
65. Abram C.L., Courtneidge S.A. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000, 254:1-13.
66. O'Laughlin-Bunner B., Radosevic N., Taylor M.L., et al. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood 2001, 98:343-350.
67. Kovarova M., Tolar P., Arudchandran R., et al. Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcepsilon receptor I aggregation. Mol Cell Biol 2001, 21:8318-8328.
68. Broudy V.C., Lin N.L., Liles W.C., et al. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 1999, 94:1979-1986.
69. Jahn T., Leifheit E., Gooch S., et al. Lipid rafts are required for Kit survival and proliferation signals. Blood 2007, 110:1739-1747.
70. Arcaro A., Aubert M., Espinosa del Hierro M.E., et al. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal 2007, 19:1081-1092.
71. Foster F.M., Traer C.J., Abraham S.M., et al. The phosphoinositide (PI) 3-kinase family. JCell Sci 2003, 116:3037-3040.
72. Fukao T., Yamada T., Tanabe M., et al. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol 2002, 3:295-304.
73. Tan B.L., Yazicioglu M.N., Ingram D., et al. Genetic evidence for convergence of c-Kit- and alpha4 integrin-mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cells. Blood 2003, 101:4725-4732.
74. Chardin P., Camonis J.H., Gale N.W., et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993, 260:1338-1343.
75. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012, 66:105-143.
76. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009, 283:125-134.
77. Kitayama H., Kanakura Y., Furitsu T., et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995, 85:790-798.
78. Boissan M., Feger F., Guillosson J.J., et al. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. JLeukoc Biol 2000, 67:135-148.
79. Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35:1143-1152.
80. Laine E., Chauvot de Beauchene I., Perahia D., et al. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol 2011, 7:e1002068.
81. Kohl T.M., Schnittger S., Ellwart J.W., et al. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005, 105:3319-3321.
82. Laine E., Auclair C., Tchertanov L. Allosteric communication across the native and mutated KIT receptor tyrosine kinase. PLoS Comput Biol 2012, 8:e1002661.
83. Zou J., Wang Y.D., Ma F.X., et al. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 2008, 72:323-332.
84. Tsujimura T., Hashimoto K., Kitayama H., et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 1999, 93:1319-1329.
85. Vendome J., Letard S., Martin F., et al. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. JMed Chem 2005, 48:6194-6201.
86. Lam L.P., Chow R.Y., Berger S.A. Atransforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. Biochem J 1999, 338(Pt 1):131-138.
87. Casteran N., De Sepulveda P., Beslu N., et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 2003, 22:4710-4722.
88. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
89. Chian R., Young S., Danilkovitch-Miagkova A., et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001, 98:1365-1373.
90. Ning Z.Q., Li J., Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001, 97:3559-3567.
91. Yang Y., Letard S., Borge L., et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010, 116:1114-1123.
92. Kozlowski M., Larose L., Lee F., et al. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 1998, 18:2089-2099.
93. Teis D., Huber L.A. The odd couple: signal transduction and endocytosis. Cell Mol Life Sci 2003, 60:2020-2033.
94. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009, 10:609-622.
95. Haugh J.M., Meyer T. Active EGF receptors have limited access to PtdIns(4,5)P(2) in endosomes: implications for phospholipase C and PI 3-kinase signaling. JCell Sci 2002, 115:303-310.
96. Kranenburg O., Verlaan I., Moolenaar W.H. Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. JBiol Chem 1999, 274:35301-35304.
97. Vieira A.V., Lamaze C., Schmid S.L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996, 274:2086-2089.
98. Wu P., Wee P., Jiang J., et al. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS One 2012, 7:e41354.
99. Hu J., Troglio F., Mukhopadhyay A., et al. F-BAR-containing adaptor CIP4 localizes to early endosomes and regulates epidermal growth factor receptor trafficking and downregulation. Cell Signal 2009, 21:1686-1697.
100. Brankatschk B., Wichert S.P., Johnson S.D., et al. Regulation of the EGF transcriptional response by endocytic sorting. Sci Signal 2012, 5:ra21.
101. Burke P., Schooler K., Wiley H.S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 2001, 12:1897-1910.
102. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351(Pt 2):289-305.
103. Teis D., Wunderlich W., Huber L.A. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell 2002, 3:803-814.
104. Taub N., Teis D., Ebner H.L., et al. Late endosomal traffic of the epidermal growth factor receptor ensures spatial and temporal fidelity of mitogen-activated protein kinase signaling. Mol Biol Cell 2007, 18:4698-4710.
105. Teis D., Taub N., Kurzbauer R., et al. p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. JCell Biol 2006, 175:861-868.
106. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010, 116:2429-2437.
107. Xiang Z., Kreisel F., Cain J., et al. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 2007, 27:267-282.
108. Kon S., Minegishi N., Tanabe K., et al. Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia. JClin Invest 2013, 123:1123-1137.
109. Levitzki A., Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006, 75:93-109.
110. Jabbour E., Lipton J.H. Acritical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk 2013, 13(6):646-656.
111. Delgado L., Giraudier S., Ortonne N., et al. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia. JAm Acad Dermatol 2013, 69:839-840.
112. Saglio G., Baccarani M. First-line therapy for chronic myeloid leukemia: new horizons and an update. Clin Lymphoma Myeloma Leuk 2010, 10:169-176.
113. Gotlib J., DeAngelo D.J., George T.I., et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood (ASH Annual Meeting Abstracts) 2010, 116:316.
114. Bai Y., Bandara G., Ching Chan E., et al. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia 2013, 27:278-285.
115. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., et al. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. JAllergy Clin Immunol 2013, 131:1213-1224. 1224.e1-4.
116. Niedoszytko M., Oude Elberink J.N., Bruinenberg M., et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy 2011, 66:229-237.
117. Ben Sahra I., Le Marchand-Brustel Y., Tanti J.F., et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol Cancer Ther 2010, 9:1092-1099.
118. O'Neill L.A., Hardie D.G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493:346-355.
119. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
120. Rosenfeld N., Aharonov R., Meiri E., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469.
121. Sethi A., Sholl L.M. Emerging evidence for MicroRNAs as regulators of cancer stem cells. Cancers (Basel) 2011, 3:3957-3971.
122. Mayoral R.J., Pipkin M.E., Pachkov M., et al. MicroRNA-221-222 regulate the cell cycle in mast cells. JImmunol 2009, 182:433-445.
123. Mayoral R.J., Deho L., Rusca N., et al. MiR-221 influences effector functions and actin cytoskeleton in mast cells. PLoS One 2011, 6:e26133.
124. Lee Y.N., Brandal S., Noel P., et al. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood 2011, 117:3629-3640.
125. Deho L., Monticelli S. Human mast cells and mastocytosis: harnessing microRNA expression as a new approach to therapy?. Arch Immunol Ther Exp (Warsz) 2010, 58:279-286.